Application of fingolimod and structural analogue of fingolimod in preparing drug for treating cerebral hemorrhage
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology similar in structure to fingolimod hydrochloride, applied in the field of fingolimod and its structural analogues, can solve the problems of no cerebral hemorrhage and achieve significant curative effect and highlight the promotion prospect
Inactive Publication Date: 2017-09-05
施福东 +10
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] In the prior art, fingolimod is only used to treat multiple sclerosis, and there is no application of this drug in the treatment of cerebral hemorrhage
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0032] 1. Preparation of drugs
[0033] Take 50g of fingolimod and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all of fingolimod to the slurry under stirring, stir all the ingredients evenly, make granules, and then Sieve, dry, and pack into capsules.
[0034] 2. Selection of experimental objects
[0035] Between March 2013 and December 2013, 11 patients with spontaneous subtentorial parenchymal hemorrhage with onset time less than 72 hours, hematoma volume between 5ml and 30ml, Glasgow coma index not less than 6, and no heart rhythm Patients with abnormalities, macular edema, tumors and immunosuppressants were used as experimental subjects, and 12 people were matched with clinical and imaging characteristics as controls.
[0036] 3. Experimental method
[0037] Patients were divided into fingolimod treatment group and control group, the control group received standard cerebral hemorrhage treatment; fingo...
Embodiment 2
[0051] Take 50g of fingolimod and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all of fingolimod to the slurry under stirring, stir all the ingredients evenly, make granules, and then Sieve and dry to form granules.
Embodiment 3
[0053] Take 50g of fingolimod, 2300g of starch, and 150g of magnesium stearate, mix 950g of starch and water to make a thin slurry, and then gradually add the remaining starch, all of fingolimod and all of the stearin to the slurry while stirring Magnesium acid, all stirred evenly, dried and compressed into tablets, film-coated to form tablets.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a novel application of fingolimod and structural analogue of fingolimod in preparing a drug for treating cerebral hemorrhage, and further determines a treatment mechanism, an active dose and an appropriate dosage form and a specific compound pointed by the structural analogue. The nature of the fingoliimod and the structural analogue of the fingolimod for alleviating lymphocytes infiltration caused by cerebral hemorrhage is made clear by virtue of experimental means, and the alleviation effect is ensured to be used as a novel target spot for treating the cerebral hemorrhage, so that the novel application of the fingolimod and the structural analogue of the fingolimod in preparing the drug for treating the cerebral hemorrhage is determined on the basis of the novel nature f the fingolimod and the structural analogue of the fingolimod. The novel application of the invention enlarges the clinical applicability of the fingolimod and the structural analogue of the fingolimod, and discloses the fact that the immune cells anticipate in the cerebral hemorrhage pathological lesion, and the drug prepared by the invention is significant in curative effect for the cerebral hemorrhage and has remarkable popularization prospect.
Description
[0001] This application is a divisional application of the Chinese application 201410136059.3 filed on April 4, 2014, entitled "Fingolimod and its structural analogs for the preparation of drugs for the treatment of cerebral hemorrhage". technical field [0002] The present invention relates to a new application of fingolimod and its structural analogues, in particular to an application of fingolimod and its structural analogues in the preparation of medicaments for treating cerebral hemorrhage. Background technique [0003] Cerebral hemorrhage is a common clinical disease with high morbidity and mortality rates. The current conventional treatment methods are surgical therapy and drug supportive therapy. Among them, surgical therapy is an effective treatment method generally recognized in the technical field. However, due to the limitations of factors such as its high risk, high cost, and high physical requirements for patients, the scope of use has been affected. At present...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more